COVID-19 is not a standard respiratory virus, it’s a serious threat to a number of vital organs. As medical specialists learn more about the virus and how it affects the human body, alarming complications are becoming evident including life-threatening blood clots in the lungs, heart and brain of COVID-19 patients.
Circulatory support research
The Alfred Heart Failure and Transplant service remains committed to ongoing research to improve the quality of lives for patients living with VADs and advancing the management of these patients for the best clinical outcomes.
The Heart Failure and Transplant service at The Alfred cares for approximately twenty five to thirty patients with ventricular assist devices (VADs) per year.
From the first clinical research trial of the Australian designed VentrAssist VAD in 2002 we remain involved in research of the newest ventricular assist devices, most recently the HeartMate III as part of an international multi-center collaborative research trial.
Particular foci of research currently include ventricular assist device driveline infections, the haemodynamics of VADs with exercise, acute and long-term rehabilitation programmes for best physical outcomes post surgical implantation, quality of life of patients living with VADs and anticoagulation monitoring.